Modifying peripheral blood-derived myeloid cells for immunotherapy
Research type
Research Study
Full title
A recent breakthrough in the battle against cancer has been the field of immunotherapy: using a patient’s immune system to destroy tumours. CAR-T therapy is one such approach, with T cells isolated from patients, modified them with anti-cancer molecules, then re-administered. We will explore the use of a different immune cell compartment, the myeloid cell family, as an alternative cell for cancer therapy and evaluate its potential to be modified to exert anti-cancer activities.
IRAS ID
253652
Contact name
Leonard W. Seymour
Contact email
Sponsor organisation
MacrophOx Ltd.
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
We will explore the use of myeloid cells isolated from peripheral blood as an immunotherapy agent. Using surplus blood provided by the NHS blood and transport service, we will study how well myeloid cells can be isolated and modified with therapeutic agents to mediate anti-cancer effects.
REC name
North East - York Research Ethics Committee
REC reference
18/NE/0302
Date of REC Opinion
19 Sep 2018
REC opinion
Favourable Opinion